COMMUNIQUÉS West-GlobeNewswire

Hydreight Reports Corporate Update and Ranks #25 on Deloitte’s 2025 Technology Fast 50™
23/10/2025
Over 295,000 VSDHOne product orders between July and September, accelerating nurse network growth and a strong balance sheet with approximately CA$18.7 million in cash; Hydreight continues to build the infrastructure [...]
Silver Creek Pharmaceuticals Announces Positive Phase 2 Results for Scp776 in Acute Ischemic Stroke
23/10/2025
Key Highlights Scp776 is the first therapy to show clinically meaningful efficacy in late-window stroke patients (treated up to 24 hours after onset) – a population with no approved drug options. Scp776 was safe and [...]
'The World’s Greatest Health Van' Travels to Ottawa: 150,000 Canadians Call for The Charter of Health Freedom
23/10/2025
OTTAWA, Ontario, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Shawn Buckley, President of the Natural Health Product Protection Association (NHPPA), is on the road — destination Parliament Hill, Ottawa. His main purpose is to [...]
Pharvaris to Present Clinical Data at the ACAAI 2025 Annual Scientific Meeting
23/10/2025
ZUG, Switzerland, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living [...]
TLX250-CDx (Zircaix) Included in Leading International Guidelines for Renal Imaging
23/10/2025
MELBOURNE, Australia and INDIANAPOLIS, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today welcomes updated guidelines from the Society of Nuclear Medicine and [...]
Tango Therapeutics Reports Positive Data from Ongoing Phase 1/2 Study with Vopimetostat (TNG462) in Patients with MTAP-deleted Cancers
23/10/2025
– 2L MTAP-del pancreatic cancer median progression free survival (mPFS) 7.2 months with an objective response rate (ORR) of 25% – – Combination studies with RAS(ON) inhibitors ongoing, data anticipated 2026 – – 49% ORR [...]
Amicus Therapeutics to Announce Third Quarter 2025 Financial Results on November 4, 2025
23/10/2025
PRINCETON, N.J., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Tuesday, November 4, 2025, at 8:30 a.m. ET to [...]
Ligand to Report Third Quarter 2025 Financial Results on November 6, 2025
23/10/2025
JUPITER, Fla., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report third quarter 2025 financial results on Thursday, November 6, 2025. The company [...]
INmune Bio Inc. to Report Third Quarter 2025 Financial Results and Provide a Corporate Update on Thursday, October 30, 2025
23/10/2025
Management to host conference call and webcast at 4:30 pm ET on that day Boca Raton, Florida, Oct. 23, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), INmune Bio Inc. (NASDAQ: INMB), a clinical- [...]
Redhook Brewing Launches Redhook 81, Celebrating Pacific Northwest Roots and the Spirit of Hard Work
23/10/2025
Redhook 81, a Cold One for Quittin’ Time SEATTLE, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Redhook Brewing , creator of the hardest working beer in the fridge and a craft brand by Tilray Brands, Inc. (NASDAQ: TLRY and TSX: [...]
Conavi Medical to Highlight Novasight Hybrid™ Imaging at TCT 2025
23/10/2025
Company to Participate in Educational Imaging Sessions and Feature Hybrid IVUS/OCT Imaging Technology TORONTO, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Conavi Medical Inc. (TSXV: CNVI) (OTCQB: CNVIF), a commercial-stage [...]
Amphista Therapeutics announces three key strategic leadership appointments to drive transition of its Targeted Glue™ protein degraders into clinical development
23/10/2025
Appointments for SVP of Clinical Operations, VP of Translational Science, and Head of Project and Portfolio Management will strengthen Amphista’s clinical development capabilities and accelerate its ambition to bring [...]
TRIDENT, a dedicated stroke outcomes trial in patients with a history of intracerebral hemorrhage (ICH), demonstrates the potential advantages of intensive blood pressure treatment with low-dose triple combination therapyTRIDENT, a dedicate
23/10/2025
GMRx2 significantly reduced the risk of recurrent stroke when added to standard of care compared to placebo Trial results were presented during a plenary session of the World Stroke Congress 2025 in Barcelona London, UK [...]
EDAP to Announce Third Quarter 2025 Financial Results on November 6, 2025
23/10/2025
EDAP to Announce Third Quarter 2025 Financial Results on November 6, 2025 Company to host conference call and webcast on Thursday, November 6 th at 8:30am EST AUSTIN, Texas, October 23, 2025 -- EDAP TMS SA (Nasdaq: EDAP [...]
BioCryst to Present New Pediatric HAE Data at the American College of Allergy, Asthma & Immunology 2025 Annual Scientific Meeting
23/10/2025
RESEARCH TRIANGLE PARK, N.C., Oct. 23, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present four abstracts at the Annual Scientific Meeting of the American [...]
Nicox : Résultats financiers du premier semestre 2025
23/10/2025
Communiqué de presse Nicox : Résultats financiers du premier semestre 2025 Les dépôts de demande d’autorisation de mise sur le marché (NDA) pour NCX 470 sont attendues en 2026 pour les Etats-Unis et la Chine La Société [...]
Nicox Provides First Half 2025 Financial Results
23/10/2025
Press Release Nicox Provides First Half 2025 Financial Results New Drug Application (NDA) submissions for NCX 470 expected in 2026 in the U.S. and China Company believes that it can finance its e xisting operations for [...]
Changes to the Roche Enlarged Corporate Executive Committee
23/10/2025
Basel, 23 October 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that Nina Schwab-Hautzinger (1975) has been appointed Head of Group Communications and a member of the enlarged Corporate Executive Committee [...]
Pharming Group to report third quarter 2025 financial results and provide business update on November 6
23/10/2025
Leiden, the Netherlands, October 23, 2025: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms that it will report its preliminary (unaudited) financial results for the third quarter 2025 [...]

Pages